Nagashima Y, Ohaki Y, Tanaka Y, Sumino K, Funabiki T, Okuyama T, et al
The sensors were then transferred into a dissociation buffer (10 mM PBS containing 0.1% bovine serum albumin and 0.02% Tween-20) to record the dissociation phase
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
additional research has demonstrated that correcting vitamin D deficiency can, in itself, increase glutathione levels Cysteine is often a limiting factor to GSH production, therefore, supplementing with L-cysteine can be used to improve GSH status in the body and has also been associated with lower levels of inflammation and insulin resistance
